A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

(Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it is "completely confident" the new version of its flagship multiple sclerosis drug, Copaxone, which features less frequent dosing, will ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...